Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series

Journal of the American College of Cardiology

Volumn 71, Issue 10, 2018, Pages 1130-1148

  Pereira, Naveen L ^a   Grogan, Martha ^a   Dec, G William ^b  

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

amyloidosis; heart failure; restrictive cardiomyopathy

Indexed keywords

GADOLINIUM;

AL AMYLOIDOSIS; ATTR AMYLOIDOSIS; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; CONSTRICTIVE PERICARDITIS; CONTRAST ENHANCEMENT; DANON DISEASE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; HEART AMYLOIDOSIS; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HUMAN; IRON OVERLOAD; LYSOSOME STORAGE DISEASE; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN KINASE AMP ACTIVATED NONCATALYTIC SUBUNIT GAMMA 2 DEFICIENT CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 85042329365     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.01.016     Document Type: Review

References (128)

1. Richardson, P., McKenna, W., Bristow, M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93 (1996), 841–842.
2. Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
3. Kushwaha, S.S., Fallon, J.T., Fuster, V., Restrictive cardiomyopathy. N Engl J Med 336 (1997), 267–276.
4. Vaitkus, P.T., Kussmaul, W.G., Constrictive pericarditis versus restrictive cardiomyopathy: a reappraisal and update of diagnostic criteria. Am Heart J 122 (1991), 1431–1441.
5. Garcia, M.J., Constrictive pericarditis versus restrictive cardiomyopathy?. J Am Coll Cardiol 67 (2016), 2061–2076.
6. Gupta, A., Singh Gulati, G., Seth, S., Sharma, S., Cardiac MRI in restrictive cardiomyopathy. Clin Radiol 67 (2012), 95–105.
7. Rapezzi, C., Arbustini, E., Caforio, A.L., et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 (2013), 1448–1458.
8. Cheng, H., Zhao, S., Jiang, S., et al. The relative atrial volume ratio and late gadolinium enhancement provide additive information to differentiate constrictive pericarditis from restrictive cardiomyopathy. J Cardiovasc Magn Reson, 13, 2011, 15.
9. Iles, L., Pfluger, H., Phrommintikul, A., et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 52 (2008), 1574–1580.
10. Muehlberg, F., Toepper, A., Fritschi, S., Prothmann, M., Schulz-Menger, J., Magnetic resonance imaging applications on infiltrative cardiomyopathies. J Thorac Imaging 31 (2016), 336–347.
11. Boynton, S.J., Geske, J.B., Dispenzieri, A., et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. J Am Coll Cardiol Img 9 (2016), 680–686.
12. Geske, J.B., Anavekar, N.S., Nishimura, R.A., Oh, J.K., Gersh, B.J., Differentiation of constriction and restriction: complex cardiovascular hemodynamics. J Am Coll Cardiol 68 (2016), 2329–2347.
13. Cooper, L.T., Baughman, K.L., Feldman, A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116 (2007), 2216–2233.
14. Bennett, M.K., Gilotra, N.A., Harrington, C., et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail 6 (2013), 676–684.
15. Rajagopalan, N., Garcia, M.J., Rodriguez, L., et al. Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 87 (2001), 86–94.
16. Ling, L.H., Oh, J.K., Tei, C., et al. Pericardial thickness measured with transesophageal echocardiography: feasibility and potential clinical usefulness. J Am Coll Cardiol 29 (1997), 1317–1323.
17. Hurrell, D.G., Nishimura, R.A., Higano, S.T., et al. Value of dynamic respiratory changes in left and right ventricular pressures for the diagnosis of constrictive pericarditis. Circulation 93 (1996), 2007–2013.
18. Hatle, L.K., Appleton, C.P., Popp, R.L., Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 79 (1989), 357–370.
19. Oh, J.K., Hatle, L.K., Seward, J.B., et al. Diagnostic role of Doppler echocardiography in constrictive pericarditis. J Am Coll Cardiol 23 (1994), 154–162.
20. Welch, T.D., Ling, L.H., Espinosa, R.E., et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging 7 (2014), 526–534.
21. Reuss, C.S., Wilansky, S.M., Lester, S.J., et al. Using mitral ‘annulus reversus’ to diagnose constrictive pericarditis. Eur J Echocardiogr 10 (2009), 372–375.
22. Ha, J.W., Oh, J.K., Ling, L.H., Nishimura, R.A., Seward, J.B., Tajik, A.J., Annulus paradoxus: transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis. Circulation 104 (2001), 976–978.
23. Garcia, M.J., Rodriguez, L., Ares, M., Griffin, B.P., Thomas, J.D., Klein, A.L., Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging. J Am Coll Cardiol 27 (1996), 108–114.
24. Sengupta, P.P., Krishnamoorthy, V.K., Abhayaratna, W.P., et al. Disparate patterns of left ventricular mechanics differentiate constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol Img 1 (2008), 29–38.
25. Masui, T., Finck, S., Higgins, C.B., Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 182 (1992), 369–373.
26. Kojima, S., Yamada, N., Goto, Y., Diagnosis of constrictive pericarditis by tagged cine magnetic resonance imaging. N Engl J Med 341 (1999), 373–374.
27. Bogabathina, H., Biederman, R.W., Lack of slippage by cardiovascular magnetic resonance imaging is sine qua non for constrictive pericarditis. Circulation 123 (2011), e418–e419.
28. Kubo, T., Gimeno, J.R., Bahl, A., et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49 (2007), 2419–2426.
29. Mogensen, J., Arbustini, E., Restrictive cardiomyopathy. Curr Opin Cardiol 24 (2009), 214–220.
30. Mogensen, J., Kubo, T., Duque, M., et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 111 (2003), 209–216.
31. Kostareva, A., Gudkova, A., Sjoberg, G., et al. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy. Int J Cardiol 131 (2009), 410–412.
32. Kaski, J.P., Syrris, P., Burch, M., et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart 94 (2008), 1478–1484.
33. Wu, W., Lu, C.X., Wang, Y.N., et al. Novel phenotype-genotype correlations of restrictive cardiomyopathy with myosin-binding protein C (MYBPC3) gene mutations tested by next-generation sequencing. J Am Heart Assoc 4 (2015), 1–7.
34. Menon, S.C., Michels, V.V., Pellikka, P.A., et al. Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology. Clin Genet 74 (2008), 445–454.
35. Sen-Chowdhry, S., Syrris, P., McKenna, W.J., Genetics of restrictive cardiomyopathy. Heart Fail Clin 6 (2010), 179–186.
36. Purevjav, E., Arimura, T., Augustin, S., et al. Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum Mol Genet 21 (2012), 2039–2053.
37. Brodehl, A., Ferrier, R.A., Hamilton, S.J., et al. Mutations in FLNC are associated with familial restrictive cardiomyopathy. Hum Mutat 37 (2016), 269–279.
38. Du, J., Liu, J., Feng, H.Z., et al. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol 294 (2008), H2604–H2613.
39. Huby, A.C., Mendsaikhan, U., Takagi, K., et al. Disturbance in Z-disk mechanosensitive proteins induced by a persistent mutant myopalladin causes familial restrictive cardiomyopathy. J Am Coll Cardiol 64 (2014), 2765–2776.
40. Capetanaki, Y., Papathanasiou, S., Diokmetzidou, A., Vatsellas, G., Tsikitis, M., Desmin related disease: a matter of cell survival failure. Curr Opin Cell Biol 32 (2015), 113–120.
41. Zhang, J., Kumar, A., Stalker, H.J., et al. Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy. Clin Genet 59 (2001), 248–256.
42. Brodehl, A., Gaertner-Rommel, A., Klauke, B., et al. The novel alphaB-crystallin (CRYAB) mutation p.D109G causes restrictive cardiomyopathy. Hum Mutat 38 (2017), 947–952.
43. Arbustini, E., Pasotti, M., Pilotto, A., et al. Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. Eur J Heart Fail 8 (2006), 477–483.
44. Burke, M.A., Cook, S.A., Seidman, J.G., Seidman, C.E., Clinical and mechanistic insights Into the genetics of cardiomyopathy. J Am Coll Cardiol 68 (2016), 2871–2886.
45. Arbustini, E., Narula, N., Tavazzi, L., et al. The MOGE(S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol 64 (2014), 304–318.
46. Yumoto, F., Lu, Q.W., Morimoto, S., et al. Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem Biophys Res Commun 338 (2005), 1519–1526.
47. Hayashi, T., Shimomura, H., Terasaki, F., et al. Collagen subtypes and matrix metalloproteinase in idiopathic restrictive cardiomyopathy. Int J Cardiol 64 (1998), 109–116.
48. Angelini, A., Calzolari, V., Thiene, G., et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am J Cardiol 80 (1997), 1046–1050.
49. Leya, F.S., Arab, D., Joyal, D., et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45 (2005), 1900–1902.
50. Reddy, P.R., Dieter, R.S., Das, P., Steen, L.H., Lewis, B.E., Leya, F.S., Utility of BNP in differentiating constrictive pericarditis from restrictive cardiomyopathy in patients with renal insufficiency. J Card Fail 13 (2007), 668–671.
51. Ammash, N.M., Seward, J.B., Bailey, K.R., Edwards, W.D., Tajik, A.J., Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101 (2000), 2490–2496.
52. Bograd, A.J., Mital, S., Schwarzenberger, J.C., et al. Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986-2006. Am J Transplant 8 (2008), 201–207.
53. Topilsky, Y., Pereira, N.L., Shah, D.K., et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail 4 (2011), 266–275.
54. Seward, J.B., Casaclang-Verzosa, G., Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol 55 (2010), 1769–1779.
55. Nagueh, S.F., Anderson-Fabry disease and other lysosomal storage disorders. Circulation 130 (2014), 1081–1090.
56. Wu, J.C., Ho, C.Y., Skali, H., et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 31 (2010), 1088–1097.
57. Linhart, A., Kampmann, C., Zamorano, J.L., et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28 (2007), 1228–1235.
58. Pieroni, M., Chimenti, C., Ricci, R., Sale, P., Russo, M.A., Frustaci, A., Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107 (2003), 1978–1984.
59. Luis, S.A., Maleszewski, J.J., Young, P.M., Schaff, H.V., Pereira, N.L., Previously unreported in women galactosidase alpha pro409Ser variant is associated with Fabry disease. Circ Cardiovasc Genet, 10, 2017, e001661.
60. Weidemann, F., Breunig, F., Beer, M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108 (2003), 1299–1301.
61. Mehta, A., Beck, M., Elliott, P., et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374 (2009), 1986–1996.
62. Ortiz, A., Abiose, A., Bichet, D.G., et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry. J Med Genet 53 (2016), 495–502.
63. Maron, B.J., Roberts, W.C., Arad, M., et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301 (2009), 1253–1259.
64. Echaniz-Laguna, A., Mohr, M., Epailly, E., et al. Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle Nerve 33 (2006), 393–397.
65. Maurer, M.S., Elliott, P., Comenzo, R., Semigran, M., Rapezzi, C., Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135 (2017), 1357–1377.
66. Lousada, I., Comenzo, R.L., Landau, H., Guthrie, S., Merlini, G., Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther 32 (2015), 920–928.
67. Kyle, R.A., Linos, A., Beard, C.M., et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79 (1992), 1817–1822.
68. Grogan, M., Scott, C.G., Kyle, R.A., et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68 (2016), 1014–1020.
69. Brenner, D.A., Jain, M., Pimentel, D.R., et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94 (2004), 1008–1010.
70. Falk, R.H., Alexander, K.M., Liao, R., Dorbala, S.A.L., (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68 (2016), 1323–1341.
71. Dubrey, S., Pollak, A., Skinner, M., Falk, R.H., Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74 (1995), 541–544.
72. Feng, D., Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116 (2007), 2420–2426.
73. Milandri, A., Longhi, S., Gagliardi, C., et al. Prevalence, risk factors and correlation with cardiac involvement of carpal tunnel syndrome in amyloidosis. Orphanet J Rare Dis, 10, 2015, P32.
74. Dispenzieri, A., Buadi, F., Kumar, S.K., et al. Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clinic Proc 90 (2015), 1054–1081.
75. Gertz, M.A., Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86 (2011), 180–186.
76. Maleszewski, J.J., Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol 24 (2015), 343–350.
77. Bellavia, D., Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 20 (2007), 1194–1202.
78. Maceira, A.M., Joshi, J., Prasad, S.K., et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111 (2005), 186–193.
79. Ruberg, F.L., T1 mapping in cardiac amyloidosis: can we get there from here?. J Am Coll Cardiol Img 6 (2013), 498–500.
80. Murtagh, B., Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95 (2005), 535–537.
81. Rapezzi, C., Merlini, G., Quarta, C.C., et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120 (2009), 1203–1212.
82. Suresh, R., Grogan, M., Maleszewski, J.J., et al. Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy. J Am Soc Echocardiogr 27 (2014), 440–447.
83. Maleszewski, J.J., Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol 22 (2013), 189–194.
84. Muchtar, E., Gertz, M.A., Kumar, S.K., et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129 (2017), 2111–2119.
85. Kumar, S., Dispenzieri, A., Lacy, M.Q., et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 (2012), 989–995.
86. Banypersad, S.M., Fontana, M., Maestrini, V., et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 36 (2015), 244–251.
87. Gertz, M.A., Landau, H., Comenzo, R.L., et al. First-in-human Phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 34 (2016), 1097–1103.
88. Richards, D.B., Cookson, L.M., Berges, A.C., et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373 (2015), 1106–1114.
89. Sperry, B.W., Ikram, A., Hachamovitch, R., et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67 (2016), 2941–2948.
90. Davis, M.K., Kale, P., Liedtke, M., et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant 15 (2015), 650–658.
91. Comenzo, R.L., Gertz, M.A., Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99 (2002), 4276–4282.
92. Gertz, M.A., Benson, M.D., Dyck, P.J., et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66 (2015), 2451–2466.
93. Lobato, L., Beirao, I., Silva, M., et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid 11 (2004), 27–37.
94. Jacobson, D.R., Pastore, R., Pool, S., et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 98 (1996), 236–238.
95. Quarta, C.C., Buxbaum, J.N., Shah, A.M., The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 372 (2015), 21–29.
96. Buxbaum, J.N., Ruberg, F.L., Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med 19 (2017), 733–742.
97. Liu, P.P., Smyth, D., Wild-type transthyretin amyloid cardiomyopathy: A missed cause of heart failure with preserved ejection fraction with evolving treatment implications. Circulation 133 (2016), 245–247.
98. Castaño, A., Narotsky, D.L., Hamid, N., et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38 (2017), 2879–2887.
99. Gonzalez-Lopez, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
100. Pinney, J.H., Whelan, C.J., Petrie, A., et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc, 2, 2013, e000098.
101. Quarta, C.C., Solomon, S.D., Uraizee, I., et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation, 129, 2014, 1840.
102. Brooks, J., Kramer, C.M., Salerno, M., Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T mapping. J Magn Reson Imaging 38 (2013), 1591–1595.
103. Narotsky, D.L., Castano, A., Weinsaft, J.W., Bokhari, S., Maurer, M.S., Wild-type transthyretin cardiac amyloidosis: Novel insights from advanced imaging. Can J Cardiol 32 (2016), 1166.e1–1166.e10.
104. Grogan, M., Dispenzieri, A., Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev 20 (2015), 155–162.
105. Gillmore, J.D., Maurer, M.S., Falk, R.H., et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133 (2016), 2404–2412.
106. Longhi, S., Guidalotti, P.L., Quarta, C.C., et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. J Am Coll Cardiol Img 7 (2014), 531–532.
107. Castano, A., Haq, M., Narotsky, D.L., et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 1 (2016), 880–889.
108. Connors, L.H., Sam, F., Skinner, M., et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133 (2016), 282–290.
109. Dubrey, S., Ackermann, E., Gillmore, J., The transthyretin amyloidoses: advances in therapy. Postgrad Med J 91 (2015), 439–448.
110. Algalarrondo, V., Dinanian, S., Juin, C., et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 9 (2012), 1069–1075.
111. Ericzon, B.G., Wilczek, H.E., Larsson, M., Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?. Transplantation 99 (2015), 1847–1854.
112. Barreiros, A.P., Post, F., Hoppe-Lotichius, M., et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 16 (2010), 314–323.
113. Nelson, L.M., Penninga, L., Sander, K., Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant 27 (2013), 203–209.
114. Dixit, N., Castano, A., Farr, M.J., et al. Rapidly progressive transthyretin-mediated amyloidosis in a Domino liver transplant recipient of a Ser23Asn donor. J Clin Neuromuscul Dis 17 (2016), 142–145.
115. Dubrey, S.W., Davidoff, R., Skinner, M., Bergethon, P., Lewis, D., Falk, R.H., Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 64 (1997), 74–80.
116. Ihse, E., Stangou, A.J., Heaton, N.D., et al. Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients. Biochem Biophys Res Commun 379 (2009), 846–850.
117. Thenappan, T., Fedson, S., Rich, J., et al. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid 21 (2014), 120–123.
118. Castano, A., Drachman, B.M., Judge, D., Maurer, M.S., Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20 (2015), 163–178.
119. Berk, J.L., Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
120. Bulawa, C.E., Connelly, S., DeVit, M., et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109 (2012), 9629–9634.
121. Coelho, T., Maia, L.F., Martins da Silva, A., Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79 (2012), 785–792.
122. Coelho, T., Adams, D., Silva, A., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369 (2013), 819–829.
123. Ackermann, E.J., Guo, S., Booten, S., Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19 Suppl 1 (2012), 43–44.
124. Cardoso, I., Saraiva, M.J., Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 20 (2006), 234–239.
125. Obici, L., Cortese, A., Lozza, A., et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19 Suppl 1 (2012), 34–36.
126. Palladini, G., Milani, P., Merlini, G., Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther 13 (2015), 1195–1211.
127. Hosoi, A., Su, Y., Torikai, M., et al. Novel antibody for the treatment of transthyretin amyloidosis. J Biol Chem 291 (2016), 25096–25105.
128. Higaki, J.N., Chakrabartty, A., Galant, N.J., et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 23 (2016), 86–97.